Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas E Delea

Showing results (11-20 of 67) with videos related to

Pageof 7
Sort By:
Journal of Medical Economics|May 4, 2019
Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasoneMay Hagiwara, Sumeet Panjabi, Arati Sharma, et al.
Current Oncology (Toronto, Ont.)|January 20, 2021
Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2- Advanced Breast CancerDaniel Stellato, Marroon Thabane, Caitlin Eichten, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 4, 2013
Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancerMay Hagiwara, Thomas E Delea, Ze Cong, et al.
Breast Cancer Research and Treatment|July 27, 2007
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspectiveThomas E Delea, Khalid El-Ouagari, Jonathan Karnon, et al.
Current Medical Research and Opinion|May 1, 2010
Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's diseaseThomas E Delea, Simu K Thomas, May Hagiwara, et al.
Journal of Medical Economics|August 21, 2018
Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemiaMay Hagiwara, Arati Sharma, Karen C Chung, et al.
Allergy and Asthma Proceedings|July 10, 2010
Adding salmeterol to fluticasone propionate or increasing the dose of fluticasone propionate in patients with asthmaThomas E Delea, May Hagiwara, David A Stempel, et al.
Clinical Therapeutics|April 15, 2008
Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthmaThomas E Delea, May Hagiwara, Richard H Stanford, et al.
Allergy and Asthma Proceedings|June 11, 2010
Stepping down to fluticasone propionate or a lower dose of fluticasone propionate/salmeterol combination in asthma patients recently initiating combination therapyMay Hagiwara, Thomas E Delea, Richard H Stanford, et al.
Clinical Breast Cancer|August 14, 2010
Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancerThomas E Delea, Charu Taneja, Oleg Sofrygin, et al.
Pageof 7

Showing results (11-20 of 67) with videos related to

Sort By:
Pageof 7
Journal of Medical Economics|May 4, 2019
Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasoneMay Hagiwara, Sumeet Panjabi, Arati Sharma, et al.
Current Oncology (Toronto, Ont.)|January 20, 2021
Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2- Advanced Breast CancerDaniel Stellato, Marroon Thabane, Caitlin Eichten, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 4, 2013
Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancerMay Hagiwara, Thomas E Delea, Ze Cong, et al.
Breast Cancer Research and Treatment|July 27, 2007
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspectiveThomas E Delea, Khalid El-Ouagari, Jonathan Karnon, et al.
Current Medical Research and Opinion|May 1, 2010
Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's diseaseThomas E Delea, Simu K Thomas, May Hagiwara, et al.
Journal of Medical Economics|August 21, 2018
Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemiaMay Hagiwara, Arati Sharma, Karen C Chung, et al.
Allergy and Asthma Proceedings|July 10, 2010
Adding salmeterol to fluticasone propionate or increasing the dose of fluticasone propionate in patients with asthmaThomas E Delea, May Hagiwara, David A Stempel, et al.
Clinical Therapeutics|April 15, 2008
Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthmaThomas E Delea, May Hagiwara, Richard H Stanford, et al.
Allergy and Asthma Proceedings|June 11, 2010
Stepping down to fluticasone propionate or a lower dose of fluticasone propionate/salmeterol combination in asthma patients recently initiating combination therapyMay Hagiwara, Thomas E Delea, Richard H Stanford, et al.
Clinical Breast Cancer|August 14, 2010
Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancerThomas E Delea, Charu Taneja, Oleg Sofrygin, et al.
Pageof 7